Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06785402 · ClinicalTrials.gov registry record · Phase 1
Ceftriaxone for Post-Treatment Lyme Disease
A Phase 1 study of Post-treatment Lyme Disease Syndrome, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06785402: Recruiting Phase 1 study of Post-treatment Lyme Disease Syndrome, sponsored by Hackensack Meridian Health.
NCT06785402 is a Phase 1 study of Post-treatment Lyme Disease Syndrome that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06785402, a Phase 1 study of Post-treatment Lyme Disease Syndrome, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Lyme disease is a public health crisis in the US. It is estimated that over 400,000 cases occur every year with 10-20% of those infected going on to develop Post-Treatment Lyme disease Syndrome (PTLDS). The goal of this study is to investigate if giving Ceftriaxone every 5 days for about 6 weeks kills the organism that produces persistent Lyme infection. Enrolled participants will be randomized 1:1 receiving either pulse-dosed ceftriaxone or placebo \[dextrose (5% in water), (D5W)\], intravenously. Participants will be evaluated at each of the study visits, and then in a follow-up phase out to 12 months. They will be unblinded at 6 months and those randomized to the placebo group will be offered pulse-dosed ceftriaxone on the same schedule as those randomized to the drug group. All patients will be followed up for a total of 12 months post treatment initiation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ceftriaxone treatment
Study Locations (1)
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-15 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 1 |
What NCT06785402 shows while recruiting
NCT06785402 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Post-treatment Lyme Disease Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06785402 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06785402 about?
NCT06785402 is a clinical study titled "Ceftriaxone for Post-Treatment Lyme Disease". Lyme disease is a public health crisis in the US. It is estimated that over 400,000 cases occur every year with 10-20% of those infected going on to develop Post-Treatment Lyme disease Syndrome (PTLDS). The goal of this study is to investigate if giving Ceftriaxone every 5 days for about 6 weeks kil...
What is the current status of trial NCT06785402?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-02-15. Estimated completion is 2027-12-01.
What conditions does trial NCT06785402 study?
This clinical trial studies the following conditions: Post-treatment Lyme Disease Syndrome.
What interventions are being tested in trial NCT06785402?
The interventions under investigation include: Placebo (DRUG), Ceftriaxone treatment (DRUG).
Who is sponsoring clinical trial NCT06785402?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06785402 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-treatment Lyme Disease Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06785402's enrollment target sits among peer trials
20 1630th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI